Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

5.600 -0.030 (-0.53%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 75 companies set new 52-week lows. 
Via Benzinga
Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model
Myriad’s MyRisk™ Hereditary Cancer test with RiskScore® provides a personalized breast cancer risk assessment for women of all ancestries 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Q3 Earnings Fall Short Of Expectations, Lowers Annual Outlook
Via Benzinga
Analyst Initiates Coverage On This Genetic Testing Stock With Ongoing Transformation
Via Benzinga
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment
From Myriad Genetics, Inc.
Via GlobeNewswire
GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care
Survey finds primary care providers wish patients would raise mental health concerns so they can provide better overall care 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information
From Myriad Genetics, Inc.
Via GlobeNewswire
Why Shares of Myriad Genetics Dropped 24% This Week
The genetic-testing company announced an acquisition and lowered its guidance. 
Via The Motley Fool
New Study Published in JCO Precision Oncology Features Data Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries
From Myriad Genetics, Inc.
Via GlobeNewswire
Why Harsco Shares Surged Over 22%; Here Are 80 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Nasdaq Down 60 Points; Eli Lilly Lowers Earnings Forecast
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping around 70 points on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers 
Via Benzinga
Dow Drops Over 200 Points; Crude Oil Rises Sharply
U.S. stocks traded lower midway through trading, with the Dow Jones dropping more than 200 points on Tuesday. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 85 stocks hit new 52-week lows. 
Via Benzinga
Why Abiomed Shares Are Trading Higher By Over 50%? Here Are 60 Stocks Moving In Tuesday's Mid-Day Session
Gainers Safe-T Group Ltd (NASDAQ: SFET) shares surged 63.7% to $0.4910 as the company said its privacy application reached over 5,000,000 downloads. 
Via Benzinga
Goodyear Tire, Catalent, Zebra Technologies And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping more than 100 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Myriad Genetics: Q3 Earnings Insights
Myriad Genetics (NASDAQ:MYGN) reported its Q3 earnings results on Tuesday, November 1, 2022 at 09:05 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Myriad Genetics Expands Consumer Access to Genetic Testing with Acquisition of Gateway Genomics and Its Market-Leading SneakPeek® Early Gender DNA Test
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Reports Third Quarter Financial Results
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Expands Board of Directors with Election of Paul M. Bisaro as New Board Member
From Myriad Genetics, Inc.
Via GlobeNewswire
Earnings Scheduled For November 1, 2022
Companies Reporting Before The Bell • BP (NYSE:BP) is estimated to report quarterly earnings at $2.07 per share on revenue of $64.76 billion. 
Via Benzinga
Earnings Preview: Myriad Genetics
Myriad Genetics (NASDAQ:MYGN) is set to give its latest quarterly earnings report on Tuesday, 2022-11-01. Here's what investors need to know before the announcement. Analysts estimate that Myriad... 
Via Benzinga
Myriad Genetics to Release Third-Quarter Financial Results on Nov. 1, 2022
From Myriad Genetics, Inc.
Via GlobeNewswire
Precision Medicine Could Get Even More Precise With Allarity Therapeutics' "Next-Generation" Diagnostics Platform
Allarity Therapeutics Inc. (NASDAQ: ALLR) is a clinical-stage pharmaceutical company focused on oncology treatments. 
Via Benzinga
Is Illumina Still the Gamechanger in Genomics Sequencing?
Genome sequencing solutions company Illumina (NASDAQ: ILMN) stock has fallen under its pandemic lows. A surprise earnings miss, and lowered guidance has caused 
Via MarketBeat
Topics Earnings Economy Lawsuit
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2022
Upgrades 
Via Benzinga
Family Cancer History Still a Mystery to Many Women, Myriad Genetics Survey Finds
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Release 2022 Second-Quarter Financial Results on Aug. 4, 2022
From Myriad Genetics, Inc.
Via GlobeNewswire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.